CMS says about 600,000 Medicare beneficiaries have joined the GLP-1 Bridge program

CMS Administrator Dr. Mehmet Oz said Monday that about 600,000 Medicare beneficiaries have enrolled in the Medicare GLP-1 Bridge program, a temporary effort that caps their monthly cost for covered GLP-1 medications at $50 ^[1]. The program began July 1, and more than half a million people have joined in its first two months ^[1].

Covered products include Wegovy (semaglutide), Zepbound (tirzepatide) in its KwikPen form, and Foundayo (orforglipron), an oral GLP-1 treatment ^[1]. The copay is the same for every participant regardless of income, and the program is authorized to run through December 31, 2027 ^[1]. CMS announced the initiative in May, describing it as a way to attach a predictable price to expensive treatments while gathering evidence on how wider coverage affects health outcomes and Medicare spending ^[1].

The $50 figure is a sharp change from what many patients faced before. Out-of-pocket costs for these drugs often ran beyond $1,000 a month, according to the report ^[1]. "These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," Oz said when the program was announced ^[1].

Who is eligible

Beneficiaries generally need Medicare Part D drug coverage and must meet clinical criteria tied to body mass index and medical history ^[1]. Medicare says people may qualify if they have a BMI of 35 or higher; a BMI of 30 or higher along with certain qualifying health conditions; or a BMI of 27 or higher plus specific cardiovascular disease histories or prediabetes ^[1].

Some Medicare beneficiaries are directed away from the Bridge. People with Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are told to pursue GLP-1 coverage through their existing drug plans instead, because they may already qualify there ^[1].

Not everyone treats the enrollment pace as good news. Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast, told Newsweek that a surge of seniors seeking the drugs for weight loss could disrupt supply for people with chronic illnesses the drugs were originally developed to treat. He also pointed to weight regain after people stop taking the medication and to possible digestive side effects ^[1]. "Ultimately, we are expanding the use of these drugs at a massive scale, and we may not fully understand the long-term consequences for years," Thompson said ^[1].

CMS has not reported how enrollment splits across the three covered products, and it has not disclosed program spending or savings figures ^[1].

Why it matters for patients

For a Medicare beneficiary who qualifies, the Bridge replaces an unpredictable monthly bill with a fixed $50 one ^[1]. On a fixed income, that gap can be the difference between filling a prescription and going without, and the enrollment count suggests the demand was there all along ^[1].

The temporary nature of the program is the central open question for anyone relying on it. "This isn't permanent coverage," said Michael Ryan, founder of MichaelRyanMoney.com ^[1]. He said that if Medicare later folds comparable GLP-1 coverage into Part D, the Bridge would have been "a temporary path to something more durable"; if it does not, people who built a household budget around $50 could face much higher costs or difficult coverage decisions ^[1].

Eligibility rules also create practical differences between patients. Two people on Medicare with similar weight and health histories can get different answers depending on whether they have Type 2 diabetes, sleep apnea, or fatty liver disease, since those patients are routed to their existing Part D plans rather than the Bridge ^[1].

What happens next

The program is authorized through December 31, 2027 ^[1]. CMS is expected to draw on data collected during the pilot to decide whether broader Medicare coverage of obesity medications should continue, change, or end ^[1]. Enrollment remains open for beneficiaries who meet the criteria, and CMS has not announced any change to the $50 copay or to the list of covered drugs ^[1]. No enrollment or savings figures beyond the CMS administrator's estimate have been reported ^[1].